Amarin

Boom-or-Bust News Is On Tap Soon for Amarin
Boom-or-Bust News Is On Tap Soon for Amarin
Motley Fool
Amarin
Vascepa
triglycerides
Flag link:
Amarin's Salyer preps for Vascepa push
Amarin's Salyer preps for Vascepa push
Medical Marketing and Media
Amarin
Vascepa
Flag link:
8 Major FDA Decisions and Trial Results to Watch for in September
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib
Flag link:
Amarin slips after adding second interim efficacy trial to PhIII CV trial
Amarin slips after adding second interim efficacy trial to PhIII CV trial
Fierce Biotech
Amarin
clinical trials
Vascepa
Flag link:
This Tiny Biopharma Has Been Bucking The Downtrend
This Tiny Biopharma Has Been Bucking The Downtrend
Motley Fool
Amarin
Vascepa
Flag link:
Amarin - Vascepa Gains Protection Until At Least 2020
Amarin - Vascepa Gains Protection Until At Least 2020
Seeking Alpha
Amarin
Vascepa
FDA
market exclusivity
Flag link:
Here's Why Amarin Corporation's Stock Rallied in April
Here's Why Amarin Corporation's Stock Rallied in April
Motley Fool
Amarin
Vascepa
Flag link:
With FDA settlement, tiny Amarin creates opening for pharma in off-label marketing
With FDA settlement, tiny Amarin creates opening for pharma in off-label marketing
Fierce Pharma
FDA
off-label
Amarin
Vascepa
Flag link:
Drugmaker settles with FDA in fish-oil drug marketing case
Drugmaker settles with FDA in fish-oil drug marketing case
Yahoo/AP
Amarin
Vascepa
FDA
off-label
Flag link:
Amarin and FDA near settlement on off-label free speech, ask court for 30 more days
Amarin and FDA near settlement on off-label free speech, ask court for 30 more days
Fierce Pharma
Amarin
FDA
off-label
free speech
Vascepa
Flag link:
3 Reasons Behind Amarin's Strong 2015
3 Reasons Behind Amarin's Strong 2015
Motley Fool
Amarin
Vascepa
Flag link:
The year's top pharma marketing controversies
The year's top pharma marketing controversies
Medical Marketing and Media
FDA
drug pricing
Amarin
social media
PBMs
AstraZeneca
Pfizer
Valeant Pharmaceuticals
drug ads
Afrezza
Flag link:
Amarin Added to NASDAQ Biotechnology Index
Amarin Added to NASDAQ Biotechnology Index
Yahoo
Amarin
NASDAQ
Flag link:
Off-label cases against the FDA move forward
Off-label cases against the FDA move forward
Medical Marketing and Media
off-label
EXPAREL
Pacira
Amarin
Vascepa
Flag link:
Amarin: Court Ruling Allowing Off-Label Marketing Should Significantly Improve Its Financial Trajectory
Amarin: Court Ruling Allowing Off-Label Marketing Should Significantly Improve Its Financial Trajectory
Seeking Alpha
Amarin
off-label
Vascepa
Flag link:
A Victory for Amarin Further Erodes FDA Regulation of Off-label Promotion
A Victory for Amarin Further Erodes FDA Regulation of Off-label Promotion
FDA Law Blog
FDA
off-label
Vascepa
free speech
Amarin
Flag link:
Judge grants relief to Amarin in off-label case
Judge grants relief to Amarin in off-label case
Medical Marketing and Media
Amarin
off-label
Vascepa
FDA
Flag link:
21st Century Cures, Amarin Court Case Advance
21st Century Cures, Amarin Court Case Advance
Medical Marketing and Media
21st Century Cures Act
Amarin
Flag link:
Amicus briefs pile up in Amarin lawsuit
Amicus briefs pile up in Amarin lawsuit
Medical Marketing and Media
Amarin
off-label
FDA
Vascepa
Flag link:
You're free to speak, FDA tells Amarin in bid to deflate free-speech suit
You're free to speak, FDA tells Amarin in bid to deflate free-speech suit
Fierce Pharma
FDA
Amarin
free speech
Vascepa
Flag link:

Pages